Expanded Access Listing Updated for Migalastat in Fabry Disease

On October 27, 2026, a clinical trial record update was posted for a physician initiated expanded access request involving migalastat. The listing, registered under identifier NCT01476163, is titled "Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease." The record lists its status as available as of this update. No phase is listed for this entry, consistent with its classification as an expanded access record rather than a standard interventional trial phase. The listing does not include results or outcome data in the information provided. This update pertains specifically to migalastat and its use in individual Fabry disease patients under an expanded access framework. No additional details on enrollment criteria, dosing, or findings were included in this event data. Readers should note that expanded access listings describe availability mechanisms for individual patient use rather than completed research conclusions. For broader context on migalastat and its current research and regulatory background, readers can consult the compound overview.